Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
SABCS 2025
What potential challenges do you foresee in transitioning from current endocrine therapies to giredestrant, based on the lidERA trial results, in ER+, HER2- early breast cancer?
Related Questions
What are your top takeaways in Radiation Oncology from SABCS 2025?
How do the ALTTO trial findings influence your choice of adjuvant endocrine therapy (AI with or without ovarian function suppression versus SERM-based therapy) for patients with HR+/HER2+ early breast cancer?
Will the results of Alliance A011104/ACRIN 6694 change your current practice regarding preoperative MRI’s in patients with newly-diagnosed, early stage breast cancer?
How will the LORETTA and COMET trials influence your treatment of low-risk DCIS?
What are your top takeaways in Medical Oncology from SABCS 2025?
Would you offer an adjuvant aromatase inhibitor following capecitabine to a post menopausal patient with ER 0%/PR 5%/HER2 0 with poor tolerance to neoadjuvant chemotherapy with residual ypT2N0M0?
Would you discontinue or dose-reduce tamoxifen in a patient who developed hepatic steatosis?
What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?
What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
